Healthcare investment firm Deerfield Management significantly increased its position in IDEAYA Biosciences (IDYA), a precision oncology company, by over 77%. The trade resulted in a holding of 2.71 million shares valued at approximately $101.17 million. This substantial purchase increased Deerfield's portfolio weight in the company to 1.06%.
This transaction was disclosed in a quarterly 13F filing and reflects a position held as of June 30, 2026. The reporting period coincided with a positive quarter for IDEAYA, which announced its registrational trial for metastatic uveal melanoma treatment met its primary endpoint and that it ended the quarter with approximately $1.24 billion in cash.